1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Acrux Limited

Acrux Limited

0.01
USD
+0.01
(+5,864.00%)
0.00EPS
8.57MMarket Cap
Mar 02Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
0.32
0.15
0.17
0.14
0.02
- -
0.01
0.01
0.01
0.03
0.02
- -
0.01
Basic EPS, GAAP
0.17
0.07
0.08
- -
-0.09
-0.05
-0.06
-0.06
-0.03
- -
-0.02
-0.02
- -
Free Cash Flow per Basic Share
0.22
0.06
0.1
0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.2
0.08
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.25
0.24
0.26
0.26
0.18
0.13
0.08
0.07
0.03
0.03
0.01
- -
- -
Tangible Book Value per Share
0.25
0.12
0.15
0.22
0.18
0.13
0.07
0.06
0.03
0.03
0.01
- -
- -
Basic Weighted Avg Shares
167
167
167
167
167
167
168
220
284
286
289
352
423
Sales/Revenue/Turnover
53
25
28
23
3
1
1
1
2
8
5
1
4
Operating Margin (%)
87
68.71
68.92
45.31
-408.67
-2,058.64
-963.85
-1,215.48
-754.28
-40.22
-168.43
-753.95
-57.82
Depreciation Expense
1
1
1
2
1
- -
1
1
1
1
1
- -
- -
Net Income, GAAP
28
11
13
- -
-14
-8
-9
-13
-10
-1
-6
-6
-1
Effective Tax Rate (%)
36.22
33.77
28.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
52.41
45.21
46.35
-1.04
-527.8
-1,319.33
-755.87
-944.58
-572.08
-9.06
-113.93
-499.58
-14.05
Working Capital
25
25
28
36
26
19
10
16
7
8
2
- -
1
LT Debt
- -
- -
- -
- -
- -
- -
2
2
2
2
2
2
1
Total Equity
42
41
44
44
30
22
13
18
9
9
3
1
1
Return on Invested Capital (%)
62.33
25.18
30.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
62.99
26.92
30.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
62.99
26.92
30.72
-0.55
-38.38
-32.08
-54.45
-80.64
-71.36
-8.59
-96.89
-276.58
-48.51

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.9%
-28.56%
43.4%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
609.76%
91.49%
-89.84%
Sales/Revenue/Turnover
48.74%
112.77%
261.18%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5
2025
- -
- -
1
2026
- -
- -
4

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
John Warmbrunn
Full Time Employees
43
Sector
Health technology
Industry
Pharmaceuticals: major
Address
103-113, Stanley Street West Melbourne VIC Australia 3003
IPO Date
Sep 29, 2004
Website
acrux.com.au
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Acrux Limited Acrux Limited is an Australia-based specialty pharmaceutical company focused on developing, registering, and commercializing a portfolio of topically applied generic pharmaceutical products, with primary emphasis on the US market; its core offerings include transdermal and topical prescription pharmaceuticals such as testosterone topical solutions, nitroglycerin ointments, acne treatments, Lenzetto, Evamist, Axiron, Ellavie, and Recuvyra, leveraging proprietary technology for drug administration through the skin, on-site laboratories, and GMP manufacturing suite. Founded in 1998 and headquartered in West Melbourne, Victoria, the company operates in Australia, the United States, Europe, and other regions, deriving revenue from licensing and commercialization partnerships while targeting affordable generic alternatives in dermatology, hormone therapy, and cardiovascular segments. Recent developments include multiple capital raisings such as $1.34 million from SPP in December 2024 and placements in early 2025 to directors including CEO Ross Dobinson and Chairman Donald Brumley; US FDA acceptance of generic applications like nitroglycerin ointment and positive remote regulatory assessments; terminations of commercialization agreements with partners including Dash Pharmaceuticals, Amring Pharmaceuticals, TruPharma, and Harris; and director share acquisitions via exercised rights and placements in 2025, reflecting ongoing funding for pipeline advancement amid a focus on topical generics.